Immunovant (IMVT) Change in Accured Expenses (2019 - 2025)

Immunovant's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2025.

• Quarterly Change in Accured Expenses fell 89.35% year-over-year to $1.6 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $8.9 million (up 561.45% YoY) and the FY2026 annual result came in at $45.0 million, up 404.31% from the prior year.
• Change in Accured Expenses was $1.6 million for Q1 2025 at Immunovant, down from $4.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $15.5 million in Q1 2024 and bottomed at -$17.3 million in Q2 2023.
• A 5-year average of $2.2 million and a median of $2.6 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 573.27% — and 2023, when it surged 312.78%.
• Immunovant's Change in Accured Expenses stood at $8.3 million in 2021, then slumped by 68.21% to $2.6 million in 2022, then slumped by 302.77% to -$5.3 million in 2023, then soared by 177.6% to $4.1 million in 2024, then tumbled by 60.27% to $1.6 million in 2025.
• Business Quant data shows IMVT's Change in Accured Expenses at $1.6 million in Q1 2025, $4.1 million in Q4 2024, and $10.7 million in Q3 2024.